Features
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds and inhibits the biologic activity against human vascular endothelial growth factor (VEGF). Bevacizumab is a humanized monoclonal antibody that recognizes and blocks vascular endothelial growth factor A ( VEGF-A).VEGF-A is a chemical signal that stimulates the growth of new blood vessels especially in cancer and other diseases. Hence Bevacizumab stops tumor growth by preventing the formation of new blood vessels by targeting and inhibiting the function of VEGF-A.